API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
Details:
Under the collaboration, OPKO will supply its proprietary long-acting GLP-2 peptide and certain Oxyntomodulin analogs, including Teduglutide, the only approved GLP-2 analog, for the development of oral tablet formulations using Entera’s proprietary oral delivery technology.
Lead Product(s): Teduglutide
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: OPKO Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 12, 2023